Senate Republicans scheduled a confirmation hearing for Food and Drug Administration Commissioner nominee Dr. Heidi Overton for Thursday, Sept. 24.
Although Overton, a former White House health policy adviser, will likely be quizzed on a variety of hot-button issues, including vaccines, prescription drug approvals, and food reform policies, her track record of supporting anti-abortion causes will likely be leveraged by Democrats hoping to score points against Republican rivals up for reelection.
Shortly after Overton’s nomination in August, the anti-abortion group Americans United for Life endorsed her for the FDA post, and other advocates celebrated her nomination.
Anti-abortion advocates hope Overton will take up their mantle in the agency responsible for regulating the abortion pill mifepristone, which has been at the center of the abortion debate since the overturning of Roe v. Wade in 2022.
If confirmed, Overton would be thrust into an ongoing litigation battle between anti-abortion activists and the FDA over telemedicine access to the abortifacient mifepristone. The abortion pill was deregulated under the Biden administration to do away with in-person screening before and after dispensing the drug, which has led to a proliferation of medication abortions nationwide, even in states where abortion is illegal.
Earlier this month, the U.S. 5th Circuit Court of Appeals held its first hearing in the case Louisiana v. FDA, with the state of Louisiana arguing that the agency’s rules allowing telehealth prescriptions for mifepristone harm women and infringe on the state’s sovereignty by undercutting its laws prohibiting elective abortion.
On top of the pending litigation, both former FDA Commissioner Dr. Marty Makary and Health and Human Services Secretary Robert F. Kennedy Jr. promised Republican senators on the committee that the agency would be conducting new safety studies on the pill, taking into account new telemedicine prescribing.
The agency has not yet delivered the results of the safety review. Some have speculated that the results of the abortion pill review are being slow-walked by the administration until after the elections.
Holding Overton’s confirmation hearing just 40 days before the 2026 midterm election in November is a risky move for incumbent Republicans, whose support for limits on abortion could be a political liability.
But Democrats on the committee will likely hone in on the issue and say that their Republican colleagues are strategizing to implement a “back-door abortion ban” that will restrict the procedure even in states where it is legal.
Overton could also be asked by Democrats on the committee about her work in the White House on Trump’s pro-family policy agenda.
The president’s pro-family agenda culminated this spring in the release of the Moms.gov resources website for new and expectant parents, which includes information about crisis pregnancy centers. Democrats and certain medical professionals claim anti-abortion activists use crisis pregnancy centers to trick or pressure women out of choosing abortion.
Overton will also likely be asked about her previous statements supporting the overturning of Roe v. Wade and the congressional effort to defund Planned Parenthood, the nation’s largest abortion provider.
The abortion-rights group Reproductive Freedom for All, formerly NARAL Pro-Choice America, is already using Overton’s nomination and her past statements to attack Republicans ahead of the midterm elections.
KEN PAXTON SUED OVER TEXAS LAW AFTER DEATH OF MOTHER DENIED AN ABORTION: WHAT TO KNOW
RFFA launched an advertisement campaign in a swing district in eastern Pennsylvania, represented by Rep. Ryan Mackenzie (R-PA), highlighting Overton’s record as an example of “anti-abortion extremism” from Republicans.
Mini Timmaraju, CEO of RFFA, said, “With the election just two months away, Republicans are stacking the administration with extremists and saying the quiet part out loud that banning abortion access is a top priority.”